Buprenorphine + Naloxone Safe for Opioid Addiction in Pregnancy
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 12, 2024 -- Pregnancies exposed to buprenorphine combined with naloxone have similar or more favorable neonatal and maternal outcomes as those exposed to buprenorphine alone, according to a study published online Aug. 12 in the Journal of the American Medical Association.
Loreen Straub, M.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues compared perinatal outcomes following prenatal exposure to buprenorphine with naloxone versus buprenorphine alone in a population-based cohort study using health care utilization data from Medicaid-insured beneficiaries. The study included 3,369 pregnant individuals exposed to buprenorphine with naloxone during the first trimester and 5,326 exposed to buprenorphine alone.
The researchers found that comparing buprenorphine combined with naloxone with buprenorphine alone resulted in significantly lower risks for neonatal abstinence syndrome, neonatal intensive care unit admission, and small for gestational age (weighted relative risks, 0.77, 0.91, and 0.86, respectively). The weighted relative risk was not significantly different for maternal morbidity (comparative rates, 2.6 versus 2.9 percent). There were no differences seen with respect to major congenital malformations overall, low birth weight, preterm birth, respiratory symptoms, or cesarean delivery. Across sensitivity analyses, the results were consistent.
"This supports the view that both formulations are reasonable options for treatment of opioid use disorder in pregnancy, affirming flexibility in collaborative treatment decision-making," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
ACC: 1999 to 2022 Saw Increase in Maternal Mortality Due to CVD
WEDNESDAY, April 2, 2025 -- From 1999 to 2022, there was a considerable increase in maternal mortality due to cardiovascular disease (CVD), according to a study presented at the...
Stimulant Involvement in Opioid OD Death Higher for Those in Physically Demanding Jobs
TUESDAY, April 1, 2025 -- A higher percentage of individuals who have psychostimulant involvement in synthetic opioid overdose deaths tend to work in physically demanding...
Evidence Supports Continuing Buprenorphine for Acute Pain in Those With Opioid Use Disorder
MONDAY, March 31, 2025 -- For patients with opioid use disorder (OUD), evidence supports continuation of buprenorphine during episodes of acute pain, but overall evidence for pain...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.